TB Vaccines Comprehensive Study by Type (Attenuated, Booster), Application (Hospitals, Clinical Labs, Pharmaceuticals), Distribution Channel (Online, Offline), Age Group (Pediatric, 16 Years 35 Years) Players and Region - Global Market Outlook to 2027

TB Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About TB Vaccines
TB Vaccines are the vaccinations which are given for the prevention of tuberculosis. TB vaccines are commonly known as Bacillus Calmette-Guerin (BCG) vaccines These vaccines gives immunity to the human body to defense against the tuberculosis. Tuberculosis kills more people in the world than any other infection. Each year about 10 million people are infected with TB and about 1.8 million die. Mycobacterium tuberculosis is the bacteria that causes tuberculosis (TB). Lung tissue is the primary target of the infection. Because the bacterium is so harmful, it is typical to cough up both mucus and blood. A severe, frequently fatal form of TB known as "military" TB, which affects many different regions of the body, including the lining of the brain, is more likely to affect children under the age of five (meninges). TB is incredibly contagious and is spread by just chatting, coughing, and sneezing. Many infected persons don't immediately become ill; instead, the germs stay dormant, reactivating years, even decades, later. Lung disease and the recognizable cough start at that point. TB vaccines not only counter the TB virus but also prevent it from spreading.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The market for TB Vaccines is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as product innovation and using various marketing strategies to gain a higher market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global TB Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck (United States), Serum Institute of India Pvt. (India), Sanofi (France), Biofabri (Spain), Intervax Ltd (Canada), AJ Biologics (Malaysia), Japan BCG Lab (Japan), Biomed Lublin (Poland), Microgen (Germany) and GreenSignal Bio Pharma Private Limited (India) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global TB Vaccines market by Type (Attenuated and Booster), Application (Hospitals, Clinical Labs and Pharmaceuticals) and Region.



On the basis of geography, the market of TB Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the TB Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Pediatric will boost the TB Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Penetration in Pharmaceutical Industry and Innovation of Highly Effective BCG Vaccines for Tuberculosis

Market Growth Drivers:
Rising Cases of Tuberculosis in Infant and Children and Government Concern About Spreading of TB Virus

Challenges:
Low Penetration in Rural Area, Government Regulations Associated with TB Vaccines, Low Tuberculosis Rate in Developing Regions and Other vaccinations as a Substitute Available in Market

Restraints:
Side Effects and Other Health Issues Associated with TB Vaccines

Opportunities:
Rising Growth in Healthcare Infrastructure

Market Leaders and their expansionary development strategies
On 14 July 2021, Spanish biopharmaceutical company Biofabri and IAVI announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC. The candidate, designed by the Spanish researcher Dr. Carlos Martin from the University of Zaragoza, was in-licensed and is being manufactured and developed by Biofabri, a subsidiary of the Zendal Group, in collaboration with University of Zaragoza, IAVI, and Europe-based Tuberculosis Vaccine Initiative (TBVI).

The formulation of international requirements for the manufacture and control of BCG vaccine was first considered by the WHO Expert Committee on Biological Standardization in its thirteenth report. In its fourteenth report, the Committee requested WHO to make arrangements as soon as possible for the formulation of such requirements. These requirements were approved by the WHO Expert Committee on Biological Standardization at its eighteenth meeting and appeared as Annex 1 to its report.

Key Target Audience
TB Vaccines Manufacturers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Attenuated
  • Booster
By Application
  • Hospitals
  • Clinical Labs
  • Pharmaceuticals
By Distribution Channel
  • Online
  • Offline

By Age Group
  • Pediatric
  • 16 Years 35 Years

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Cases of Tuberculosis in Infant and Children
      • 3.2.2. Government Concern About Spreading of TB Virus
    • 3.3. Market Challenges
      • 3.3.1. Low Penetration in Rural Area
      • 3.3.2. Government Regulations Associated with TB Vaccines
      • 3.3.3. Low Tuberculosis Rate in Developing Regions
      • 3.3.4. Other vaccinations as a Substitute Available in Market
    • 3.4. Market Trends
      • 3.4.1. Technological Penetration in Pharmaceutical Industry
      • 3.4.2. Innovation of Highly Effective BCG Vaccines for Tuberculosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global TB Vaccines, by Type, Application, Distribution Channel, Age Group and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global TB Vaccines (Value)
      • 5.2.1. Global TB Vaccines by: Type (Value)
        • 5.2.1.1. Attenuated
        • 5.2.1.2. Booster
      • 5.2.2. Global TB Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinical Labs
        • 5.2.2.3. Pharmaceuticals
      • 5.2.3. Global TB Vaccines by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global TB Vaccines by: Age Group (Value)
        • 5.2.4.1. Pediatric
        • 5.2.4.2. 16 Years 35 Years
      • 5.2.5. Global TB Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global TB Vaccines (Price)
      • 5.3.1. Global TB Vaccines by: Type (Price)
  • 6. TB Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Serum Institute of India Pvt. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biofabri (Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Intervax Ltd (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AJ Biologics (Malaysia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Japan BCG Lab (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biomed Lublin (Poland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Microgen (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GreenSignal Bio Pharma Private Limited (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global TB Vaccines Sale, by Type, Application, Distribution Channel, Age Group and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global TB Vaccines (Value)
      • 7.2.1. Global TB Vaccines by: Type (Value)
        • 7.2.1.1. Attenuated
        • 7.2.1.2. Booster
      • 7.2.2. Global TB Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinical Labs
        • 7.2.2.3. Pharmaceuticals
      • 7.2.3. Global TB Vaccines by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global TB Vaccines by: Age Group (Value)
        • 7.2.4.1. Pediatric
        • 7.2.4.2. 16 Years 35 Years
      • 7.2.5. Global TB Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global TB Vaccines (Price)
      • 7.3.1. Global TB Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. TB Vaccines: by Type(USD Million)
  • Table 2. TB Vaccines Attenuated , by Region USD Million (2016-2021)
  • Table 3. TB Vaccines Booster , by Region USD Million (2016-2021)
  • Table 4. TB Vaccines: by Application(USD Million)
  • Table 5. TB Vaccines Hospitals , by Region USD Million (2016-2021)
  • Table 6. TB Vaccines Clinical Labs , by Region USD Million (2016-2021)
  • Table 7. TB Vaccines Pharmaceuticals , by Region USD Million (2016-2021)
  • Table 8. TB Vaccines: by Distribution Channel(USD Million)
  • Table 9. TB Vaccines Online , by Region USD Million (2016-2021)
  • Table 10. TB Vaccines Offline , by Region USD Million (2016-2021)
  • Table 11. TB Vaccines: by Age Group(USD Million)
  • Table 12. TB Vaccines Pediatric , by Region USD Million (2016-2021)
  • Table 13. TB Vaccines 16 Years 35 Years , by Region USD Million (2016-2021)
  • Table 14. South America TB Vaccines, by Country USD Million (2016-2021)
  • Table 15. South America TB Vaccines, by Type USD Million (2016-2021)
  • Table 16. South America TB Vaccines, by Application USD Million (2016-2021)
  • Table 17. South America TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 18. South America TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 19. Brazil TB Vaccines, by Type USD Million (2016-2021)
  • Table 20. Brazil TB Vaccines, by Application USD Million (2016-2021)
  • Table 21. Brazil TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 22. Brazil TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 23. Argentina TB Vaccines, by Type USD Million (2016-2021)
  • Table 24. Argentina TB Vaccines, by Application USD Million (2016-2021)
  • Table 25. Argentina TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 26. Argentina TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 27. Rest of South America TB Vaccines, by Type USD Million (2016-2021)
  • Table 28. Rest of South America TB Vaccines, by Application USD Million (2016-2021)
  • Table 29. Rest of South America TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 30. Rest of South America TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 31. Asia Pacific TB Vaccines, by Country USD Million (2016-2021)
  • Table 32. Asia Pacific TB Vaccines, by Type USD Million (2016-2021)
  • Table 33. Asia Pacific TB Vaccines, by Application USD Million (2016-2021)
  • Table 34. Asia Pacific TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 35. Asia Pacific TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 36. China TB Vaccines, by Type USD Million (2016-2021)
  • Table 37. China TB Vaccines, by Application USD Million (2016-2021)
  • Table 38. China TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 39. China TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 40. Japan TB Vaccines, by Type USD Million (2016-2021)
  • Table 41. Japan TB Vaccines, by Application USD Million (2016-2021)
  • Table 42. Japan TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 43. Japan TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 44. India TB Vaccines, by Type USD Million (2016-2021)
  • Table 45. India TB Vaccines, by Application USD Million (2016-2021)
  • Table 46. India TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 47. India TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 48. South Korea TB Vaccines, by Type USD Million (2016-2021)
  • Table 49. South Korea TB Vaccines, by Application USD Million (2016-2021)
  • Table 50. South Korea TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 51. South Korea TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 52. Australia TB Vaccines, by Type USD Million (2016-2021)
  • Table 53. Australia TB Vaccines, by Application USD Million (2016-2021)
  • Table 54. Australia TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 55. Australia TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 56. Rest of Asia-Pacific TB Vaccines, by Type USD Million (2016-2021)
  • Table 57. Rest of Asia-Pacific TB Vaccines, by Application USD Million (2016-2021)
  • Table 58. Rest of Asia-Pacific TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 60. Europe TB Vaccines, by Country USD Million (2016-2021)
  • Table 61. Europe TB Vaccines, by Type USD Million (2016-2021)
  • Table 62. Europe TB Vaccines, by Application USD Million (2016-2021)
  • Table 63. Europe TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 64. Europe TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 65. Germany TB Vaccines, by Type USD Million (2016-2021)
  • Table 66. Germany TB Vaccines, by Application USD Million (2016-2021)
  • Table 67. Germany TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 68. Germany TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 69. France TB Vaccines, by Type USD Million (2016-2021)
  • Table 70. France TB Vaccines, by Application USD Million (2016-2021)
  • Table 71. France TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 72. France TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 73. Italy TB Vaccines, by Type USD Million (2016-2021)
  • Table 74. Italy TB Vaccines, by Application USD Million (2016-2021)
  • Table 75. Italy TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 76. Italy TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 77. United Kingdom TB Vaccines, by Type USD Million (2016-2021)
  • Table 78. United Kingdom TB Vaccines, by Application USD Million (2016-2021)
  • Table 79. United Kingdom TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 80. United Kingdom TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 81. Netherlands TB Vaccines, by Type USD Million (2016-2021)
  • Table 82. Netherlands TB Vaccines, by Application USD Million (2016-2021)
  • Table 83. Netherlands TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 84. Netherlands TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 85. Rest of Europe TB Vaccines, by Type USD Million (2016-2021)
  • Table 86. Rest of Europe TB Vaccines, by Application USD Million (2016-2021)
  • Table 87. Rest of Europe TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 88. Rest of Europe TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 89. MEA TB Vaccines, by Country USD Million (2016-2021)
  • Table 90. MEA TB Vaccines, by Type USD Million (2016-2021)
  • Table 91. MEA TB Vaccines, by Application USD Million (2016-2021)
  • Table 92. MEA TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 93. MEA TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 94. Middle East TB Vaccines, by Type USD Million (2016-2021)
  • Table 95. Middle East TB Vaccines, by Application USD Million (2016-2021)
  • Table 96. Middle East TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 97. Middle East TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 98. Africa TB Vaccines, by Type USD Million (2016-2021)
  • Table 99. Africa TB Vaccines, by Application USD Million (2016-2021)
  • Table 100. Africa TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 101. Africa TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 102. North America TB Vaccines, by Country USD Million (2016-2021)
  • Table 103. North America TB Vaccines, by Type USD Million (2016-2021)
  • Table 104. North America TB Vaccines, by Application USD Million (2016-2021)
  • Table 105. North America TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 106. North America TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 107. United States TB Vaccines, by Type USD Million (2016-2021)
  • Table 108. United States TB Vaccines, by Application USD Million (2016-2021)
  • Table 109. United States TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 110. United States TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 111. Canada TB Vaccines, by Type USD Million (2016-2021)
  • Table 112. Canada TB Vaccines, by Application USD Million (2016-2021)
  • Table 113. Canada TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 114. Canada TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 115. Mexico TB Vaccines, by Type USD Million (2016-2021)
  • Table 116. Mexico TB Vaccines, by Application USD Million (2016-2021)
  • Table 117. Mexico TB Vaccines, by Distribution Channel USD Million (2016-2021)
  • Table 118. Mexico TB Vaccines, by Age Group USD Million (2016-2021)
  • Table 119. TB Vaccines: by Type(USD/Units)
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. TB Vaccines: by Type(USD Million)
  • Table 131. TB Vaccines Attenuated , by Region USD Million (2022-2027)
  • Table 132. TB Vaccines Booster , by Region USD Million (2022-2027)
  • Table 133. TB Vaccines: by Application(USD Million)
  • Table 134. TB Vaccines Hospitals , by Region USD Million (2022-2027)
  • Table 135. TB Vaccines Clinical Labs , by Region USD Million (2022-2027)
  • Table 136. TB Vaccines Pharmaceuticals , by Region USD Million (2022-2027)
  • Table 137. TB Vaccines: by Distribution Channel(USD Million)
  • Table 138. TB Vaccines Online , by Region USD Million (2022-2027)
  • Table 139. TB Vaccines Offline , by Region USD Million (2022-2027)
  • Table 140. TB Vaccines: by Age Group(USD Million)
  • Table 141. TB Vaccines Pediatric , by Region USD Million (2022-2027)
  • Table 142. TB Vaccines 16 Years 35 Years , by Region USD Million (2022-2027)
  • Table 143. South America TB Vaccines, by Country USD Million (2022-2027)
  • Table 144. South America TB Vaccines, by Type USD Million (2022-2027)
  • Table 145. South America TB Vaccines, by Application USD Million (2022-2027)
  • Table 146. South America TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 147. South America TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 148. Brazil TB Vaccines, by Type USD Million (2022-2027)
  • Table 149. Brazil TB Vaccines, by Application USD Million (2022-2027)
  • Table 150. Brazil TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 151. Brazil TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 152. Argentina TB Vaccines, by Type USD Million (2022-2027)
  • Table 153. Argentina TB Vaccines, by Application USD Million (2022-2027)
  • Table 154. Argentina TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 155. Argentina TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 156. Rest of South America TB Vaccines, by Type USD Million (2022-2027)
  • Table 157. Rest of South America TB Vaccines, by Application USD Million (2022-2027)
  • Table 158. Rest of South America TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 159. Rest of South America TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 160. Asia Pacific TB Vaccines, by Country USD Million (2022-2027)
  • Table 161. Asia Pacific TB Vaccines, by Type USD Million (2022-2027)
  • Table 162. Asia Pacific TB Vaccines, by Application USD Million (2022-2027)
  • Table 163. Asia Pacific TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 164. Asia Pacific TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 165. China TB Vaccines, by Type USD Million (2022-2027)
  • Table 166. China TB Vaccines, by Application USD Million (2022-2027)
  • Table 167. China TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 168. China TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 169. Japan TB Vaccines, by Type USD Million (2022-2027)
  • Table 170. Japan TB Vaccines, by Application USD Million (2022-2027)
  • Table 171. Japan TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 172. Japan TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 173. India TB Vaccines, by Type USD Million (2022-2027)
  • Table 174. India TB Vaccines, by Application USD Million (2022-2027)
  • Table 175. India TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 176. India TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 177. South Korea TB Vaccines, by Type USD Million (2022-2027)
  • Table 178. South Korea TB Vaccines, by Application USD Million (2022-2027)
  • Table 179. South Korea TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 180. South Korea TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 181. Australia TB Vaccines, by Type USD Million (2022-2027)
  • Table 182. Australia TB Vaccines, by Application USD Million (2022-2027)
  • Table 183. Australia TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 184. Australia TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 185. Rest of Asia-Pacific TB Vaccines, by Type USD Million (2022-2027)
  • Table 186. Rest of Asia-Pacific TB Vaccines, by Application USD Million (2022-2027)
  • Table 187. Rest of Asia-Pacific TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 188. Rest of Asia-Pacific TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 189. Europe TB Vaccines, by Country USD Million (2022-2027)
  • Table 190. Europe TB Vaccines, by Type USD Million (2022-2027)
  • Table 191. Europe TB Vaccines, by Application USD Million (2022-2027)
  • Table 192. Europe TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 193. Europe TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 194. Germany TB Vaccines, by Type USD Million (2022-2027)
  • Table 195. Germany TB Vaccines, by Application USD Million (2022-2027)
  • Table 196. Germany TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 197. Germany TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 198. France TB Vaccines, by Type USD Million (2022-2027)
  • Table 199. France TB Vaccines, by Application USD Million (2022-2027)
  • Table 200. France TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 201. France TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 202. Italy TB Vaccines, by Type USD Million (2022-2027)
  • Table 203. Italy TB Vaccines, by Application USD Million (2022-2027)
  • Table 204. Italy TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 205. Italy TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 206. United Kingdom TB Vaccines, by Type USD Million (2022-2027)
  • Table 207. United Kingdom TB Vaccines, by Application USD Million (2022-2027)
  • Table 208. United Kingdom TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 209. United Kingdom TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 210. Netherlands TB Vaccines, by Type USD Million (2022-2027)
  • Table 211. Netherlands TB Vaccines, by Application USD Million (2022-2027)
  • Table 212. Netherlands TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 213. Netherlands TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 214. Rest of Europe TB Vaccines, by Type USD Million (2022-2027)
  • Table 215. Rest of Europe TB Vaccines, by Application USD Million (2022-2027)
  • Table 216. Rest of Europe TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 217. Rest of Europe TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 218. MEA TB Vaccines, by Country USD Million (2022-2027)
  • Table 219. MEA TB Vaccines, by Type USD Million (2022-2027)
  • Table 220. MEA TB Vaccines, by Application USD Million (2022-2027)
  • Table 221. MEA TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 222. MEA TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 223. Middle East TB Vaccines, by Type USD Million (2022-2027)
  • Table 224. Middle East TB Vaccines, by Application USD Million (2022-2027)
  • Table 225. Middle East TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 226. Middle East TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 227. Africa TB Vaccines, by Type USD Million (2022-2027)
  • Table 228. Africa TB Vaccines, by Application USD Million (2022-2027)
  • Table 229. Africa TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 230. Africa TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 231. North America TB Vaccines, by Country USD Million (2022-2027)
  • Table 232. North America TB Vaccines, by Type USD Million (2022-2027)
  • Table 233. North America TB Vaccines, by Application USD Million (2022-2027)
  • Table 234. North America TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 235. North America TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 236. United States TB Vaccines, by Type USD Million (2022-2027)
  • Table 237. United States TB Vaccines, by Application USD Million (2022-2027)
  • Table 238. United States TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 239. United States TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 240. Canada TB Vaccines, by Type USD Million (2022-2027)
  • Table 241. Canada TB Vaccines, by Application USD Million (2022-2027)
  • Table 242. Canada TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 243. Canada TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 244. Mexico TB Vaccines, by Type USD Million (2022-2027)
  • Table 245. Mexico TB Vaccines, by Application USD Million (2022-2027)
  • Table 246. Mexico TB Vaccines, by Distribution Channel USD Million (2022-2027)
  • Table 247. Mexico TB Vaccines, by Age Group USD Million (2022-2027)
  • Table 248. TB Vaccines: by Type(USD/Units)
  • Table 249. Research Programs/Design for This Report
  • Table 250. Key Data Information from Secondary Sources
  • Table 251. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global TB Vaccines: by Type USD Million (2016-2021)
  • Figure 5. Global TB Vaccines: by Application USD Million (2016-2021)
  • Figure 6. Global TB Vaccines: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global TB Vaccines: by Age Group USD Million (2016-2021)
  • Figure 8. South America TB Vaccines Share (%), by Country
  • Figure 9. Asia Pacific TB Vaccines Share (%), by Country
  • Figure 10. Europe TB Vaccines Share (%), by Country
  • Figure 11. MEA TB Vaccines Share (%), by Country
  • Figure 12. North America TB Vaccines Share (%), by Country
  • Figure 13. Global TB Vaccines: by Type USD/Units (2016-2021)
  • Figure 14. Global TB Vaccines share by Players 2021 (%)
  • Figure 15. Global TB Vaccines share by Players (Top 3) 2021(%)
  • Figure 16. Global TB Vaccines share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck (United States) Revenue: by Geography 2021
  • Figure 20. Serum Institute of India Pvt. (India) Revenue, Net Income and Gross profit
  • Figure 21. Serum Institute of India Pvt. (India) Revenue: by Geography 2021
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2021
  • Figure 24. Biofabri (Spain) Revenue, Net Income and Gross profit
  • Figure 25. Biofabri (Spain) Revenue: by Geography 2021
  • Figure 26. Intervax Ltd (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Intervax Ltd (Canada) Revenue: by Geography 2021
  • Figure 28. AJ Biologics (Malaysia) Revenue, Net Income and Gross profit
  • Figure 29. AJ Biologics (Malaysia) Revenue: by Geography 2021
  • Figure 30. Japan BCG Lab (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Japan BCG Lab (Japan) Revenue: by Geography 2021
  • Figure 32. Biomed Lublin (Poland) Revenue, Net Income and Gross profit
  • Figure 33. Biomed Lublin (Poland) Revenue: by Geography 2021
  • Figure 34. Microgen (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Microgen (Germany) Revenue: by Geography 2021
  • Figure 36. GreenSignal Bio Pharma Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. GreenSignal Bio Pharma Private Limited (India) Revenue: by Geography 2021
  • Figure 38. Global TB Vaccines: by Type USD Million (2022-2027)
  • Figure 39. Global TB Vaccines: by Application USD Million (2022-2027)
  • Figure 40. Global TB Vaccines: by Distribution Channel USD Million (2022-2027)
  • Figure 41. Global TB Vaccines: by Age Group USD Million (2022-2027)
  • Figure 42. South America TB Vaccines Share (%), by Country
  • Figure 43. Asia Pacific TB Vaccines Share (%), by Country
  • Figure 44. Europe TB Vaccines Share (%), by Country
  • Figure 45. MEA TB Vaccines Share (%), by Country
  • Figure 46. North America TB Vaccines Share (%), by Country
  • Figure 47. Global TB Vaccines: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Merck (United States)
  • Serum Institute of India Pvt. (India)
  • Sanofi (France)
  • Biofabri (Spain)
  • Intervax Ltd (Canada)
  • AJ Biologics (Malaysia)
  • Japan BCG Lab (Japan)
  • Biomed Lublin (Poland)
  • Microgen (Germany)
  • GreenSignal Bio Pharma Private Limited (India)
Select User Access Type

Key Highlights of Report


Sep 2022 212 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck (United States), Serum Institute of India Pvt. (India), Sanofi (France), Biofabri (Spain), Intervax Ltd (Canada), AJ Biologics (Malaysia), Japan BCG Lab (Japan), Biomed Lublin (Poland), Microgen (Germany) and GreenSignal Bio Pharma Private Limited (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Penetration in Pharmaceutical Industry " is seen as one of major influencing trends for TB Vaccines Market during projected period 2021-2027.
The TB Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global TB Vaccines Report?